105 related articles for article (PubMed ID: 8104489)
1. Artifacts in the analysis of thioridazine and other neuroleptics.
Eap CB; Koeb L; Baumann P
J Pharm Biomed Anal; 1993 Jun; 11(6):451-7. PubMed ID: 8104489
[TBL] [Abstract][Full Text] [Related]
2. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
Eap CB; Souche A; Koeb L; Baumann P
Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat.
Lin G; Hawes EM; McKay G; Korchinski ED; Midha KK
Xenobiotica; 1993 Oct; 23(10):1059-74. PubMed ID: 8259689
[TBL] [Abstract][Full Text] [Related]
4. LC-MS-MS analysis of the neuroleptics clozapine, flupentixol, haloperidol, penfluridol, thioridazine, and zuclopenthixol in hair obtained from psychiatric patients.
Weinmann W; Müller C; Vogt S; Frei A
J Anal Toxicol; 2002; 26(5):303-7. PubMed ID: 12166818
[TBL] [Abstract][Full Text] [Related]
5. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
Niedzwiecki DM; Mailman RB; Cubeddu LX
J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
[TBL] [Abstract][Full Text] [Related]
6. Absorption and excretion of thioridazine and mesoridazine in man.
Charalampous KD; Johnson PC; Estevez V
Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
[TBL] [Abstract][Full Text] [Related]
8. GLC analysis of thioridazine, mesoridazine, and their metabolites.
Dinovo EC; Gottschalk LA; Nandi BR; Geddes PG
J Pharm Sci; 1976 May; 65(5):667-9. PubMed ID: 932933
[TBL] [Abstract][Full Text] [Related]
9. Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma.
Eap CB; Koeb L; Powell K; Baumann P
J Chromatogr B Biomed Appl; 1995 Jul; 669(2):271-9. PubMed ID: 7581903
[TBL] [Abstract][Full Text] [Related]
10. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
Pol J Pharmacol; 1998; 50(6):431-42. PubMed ID: 10385926
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and properties of haptens for the development of radioimmunoassays for thioridazine, mesoridazine, and sulforidazine.
Chakraborty BS; Sardessai MS; Jaworski TJ; Midha KK; Hawes EM
Pharm Res; 1987 Jun; 4(3):207-13. PubMed ID: 3509283
[TBL] [Abstract][Full Text] [Related]
13. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous assay of thioridazine and its major metabolites in plasma at single dosage levels with a novel report of two ring sulfoxides of thioridazine.
Wells CE; Juenge EC; Furman WB
J Pharm Sci; 1983 Jun; 72(6):622-5. PubMed ID: 6875822
[TBL] [Abstract][Full Text] [Related]
16. Identification of a metabolite of thioridazine and mesoridazine from human plasma.
Gruenke LD; Craig JC
Res Commun Chem Pathol Pharmacol; 1975 Feb; 10(2):221-5. PubMed ID: 1162173
[TBL] [Abstract][Full Text] [Related]
17. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites.
Cohen BM; Lipinski JF; Waternaux C
Psychopharmacology (Berl); 1989; 97(4):481-8. PubMed ID: 2498945
[TBL] [Abstract][Full Text] [Related]
18. S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteers.
Chakraborty BS; Hawes EM; McKay G; Hubbard JW; Korchinski ED; Midha KK; Choc MG; Robinson WT
Drug Metabol Drug Interact; 1988; 6(3-4):425-37. PubMed ID: 3271648
[TBL] [Abstract][Full Text] [Related]
19. Racemization and degradation of thioridazine and thioridazine 2-sulfone in human plasma and aqueous solutions.
Masetto de Gaitani C; Martinez AS; Bonato PS
Chirality; 2003 Jun; 15(6):479-85. PubMed ID: 12774286
[TBL] [Abstract][Full Text] [Related]
20. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
